Mechanisms exploration of Xiaojin Pills on lung cancer based on metabolomics and network pharmacology. (17th April 2021)

• Record Type: Journal Article
• Authors: Cao, Bo; Lin, Junzhi; Wu, Zhenfeng; Liu, Huimin; Zhang, Dingkun; Xu, Hong; Xu, Runchun; Han, Li
• Is Part Of: Journal of pharmacy and pharmacology. Volume 73:Number 8(2021)
• Page Start: 1071
• Page End: 1079
• Publication Date: 2021-04-17
• Subjects: Xiaojin Pills -- lung cancer -- metabolomics -- network pharmacology; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1093/jpp/rgab050
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objectives: This study was designed to evaluate the pharmacological activity and therapeutic mechanism of Xiaojin Pills (XJW) on lung cancer. Methods: Mice were orally administered with Xiaojin Pills for 21 days. Tumour samples were collected to evaluate the antilung cancer effect, and blood samples were collected to identify differential metabolites with metabolomics. Through the analysis of network pharmacology, the active ingredients and targets related to XJW therapy for lung cancer were filtered. Key findings: Different expression of seven metabolites related to seven pathways, including Arachidonic acid metabolism, Citrate cycle, tryptophan metabolism, glyoxylate and dicarboxylate metabolism, arginine and proline metabolism, primary bile acid biosynthesis and nicotinate and nicotinamide metabolism, were demonstrated to explain the efficacy of XJW in the treatment of lung cancer. Furthermore, a total of 19 active ingredients (ursolic acid, α-thujone, pelargonidin, succinic acid, boswellic acid, muscone, daidzein, xanthorrhizol, isoeugenol, oleic acid, β-caryophyllene, vanillin, β-sitosterol, lupeol, palmitic acid, eugenol, methylbutenol, β-elemene and quercetin) acted directly on 9 targets (CAT, PTGS2, PTGS1, CTH, ABTA, ALT1, ME2, AGXT and AGXT 2) and regulated 3 out of 7 metabolites (3-Hydroxyanthranilic acid, Pyruvate and Prostaglandin G2). Conclusions: Through metabolomics and network pharmacology analyses, this study demonstrated that the major metabolites of XJW in treating lung cancer were regulated by multitarget and multicomponent interaction network.